PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 4, 2017, Pages

  Schmidt, Amand F ^a   Pearce, Lucy S ^b   Wilkins, John T ^c   Overington, John P ^d   Hingorani, Aroon D ^a   Casas, Juan P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MEDICINES DISCOVERY CATAPULT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PCSK9; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASE 9 INHIBITOR; UNCLASSIFIED DRUG; ALIROCUMAB; BOCOCIZUMAB; CHOLINERGIC RECEPTOR BLOCKING AGENT; EVOLOCUMAB; RG7652;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; MALIGNANT NEOPLASM; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; META ANALYSIS; MIDDLE AGED; PROCEDURES; TIME FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL, LDL; CHOLINERGIC ANTAGONISTS; EZETIMIBE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PRIMARY PREVENTION; PROPROTEIN CONVERTASE 9; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; TIME FACTORS;

EID: 85018245564     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011748.pub2     Document Type: Review

References (111)

1. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. American Journal of Cardiology 2015;115(9):1212-21. 5479801
2. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. New England Journal of Medicine 2014;370:1809-19. 5479803
3. Tingley W, Mosesova S, Baruch A, Davis JD, Budha N, Vilimovskij A, et al. Effects of RG7652, a monoclonal antibody against proprotein convertase Subtilisin/Kexin type 9, on LDL cholesterol in patients with coronary heart disease or high risk: results from the EQUATOR study. European Heart Journal. 2014:371. 5479805
4. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine 2017;online:1-10. 5479807
5. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. Journal of Clinical Lipidology 2015;9(6):758-69. 5479809
6. Stroes E, Guyton JR, Farnier M, Rader D, Moriarty PM, Bergeron J, et al. Efficacy and safety of 150 mg and 300 mg every 3 weeks in patients with poorly controlled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies. Journal of the American College of Cardiology. 2015; Vol. abstract:Exhibit 99.1. 5479811
7. Stroes E, Guyton JR, Farnier M, Rader D, Moriarty PM, Bergeron J, et al. Efficacy and safety of 150 mg and 300 mg every 3 weeks in patients with poorly controlled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies. Journal of the American College of Cardiology. 2015; Vol. abstract:Exhibit 99.1. 5479813
8. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. American Heart Journal 2015;169(6):906. 5479815
9. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. European Heart Journal 2015;36(19):1186-94. 5479817
10. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal 2015;36(43):2996-3003. 5479819
11. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal 2015;36(43):2996-3003. 5479821
12. Ginsberg HN, Rader DJ, Raal F, Guyton JR, Lorenzato C, Pordy R, et al. ODYSSEY HIGH FH: Efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Conference abstract. Published online 2014. 5479823
13. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. New England Journal of Medicine 2015;372(16):1489-99. 5479825
14. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJP, Colhoun HM, Robinson JG, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. International Journal of Cardiology 2014;176:55-61. 5479827
15. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. Journal of Clinical Endocrinology and Metabolism 2015;100(8):3140-8. 5479829
16. Farnier M, Jones P, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerorsis 2016;244:138-46. 5479831
17. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014;129:234-43. 5479833
18. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New England Journal of Medicine 2015;372(16):1500-9. 5479835
19. Ridker PM, Revking J, Amarenco P, Brunell R, Curto M, Civeria F, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. New England Journal of Medicine 2017;online:1-13. 5479837
20. Baruch A, Peng K, Leabman M, Budha N, Luca D, Cowan KJ, et al. Effect of RG7652, a mAb against PCSK9, on apolipoprotein B, oxidized LDL, lipoprotein(A) and lipoprotein-associated phospholipase a2 in healthy individuals with elevated LDL-C. Circulation. 2013; Vol. 22. 5479839
21. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, et al. Clinical profile of statin intolerance in the phase 3 gauss-2 study. Canadian Journal of Cardiology. 2014:S79. 5479841
22. Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of National Cholesterol Education Program-Adult Treatment Panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Journal of the American College of Cardiology 2014;63:430-3. 5479843
23. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. Journal of the American College of Cardiology 2012;60:1888-98. 5479845
24. Dufour R, Moriarty PM, Genestin E, Sasiela WJ, Du Y, Ferrand AC, et al. Effect of REGN727/SAR236553 anti-proprotein convertase subtilisin/kexin type 9 fully human monoclonal antibody in patients with elevated triglycerides/low high-density lipoprotein cholesterol: data from three phase 2 studies (NCT:01266876; 01288469; 01288443). Circulation. 2012. 5479847
25. Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D, et al. Effect of SAR236553/REGN727 fully human monoclonal anti-proprotein convertase subtilisin/kexin type 9 antibody on plasma lipoprotein(a) concentrations: pooled analysis from three phase 2 studies (NCT:01266876; 01288469; 01288443). Circulation. 2012. 5479849
26. Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D, et al. Alirocumab, a fully human monoclonal antibody to PCSK9, reduces high plasma lp(a) concentration: pooled analysis of 352 patients from phase 2. Journal of Clinical Lipidology 2013;7(3):283-4. 5479851
27. Gumbiner B, Udata C, Joh T, Liang H, Wan H, Shelton D, et al. The effects of multiple dose administration of RN316 (PF-04950619), a humanized IgG2a monoclonal antibody binding proprotein convertase snbtilisin kexin type 9, in hypercholesterolemic subjects. Circulation. 2012; Vol. 126, issue 21. 5479853
28. Hopkins PN, Swergold GD, Mellis S, Bruckert E, Luc G, Mendoza J, et al. A randomized placebo-phase clinical trial with the monoclonal antibody alirocumab demonstrates reductions in low-density lipoprotein cholesterol in patients with proprotein convertase subtilisin/kexin type 9 gain-of-function mutations. Circulation. 2013. 5479855
29. Jones PH, Bays H, Chaudhari U, Pordy R, Lorenzato C, Miller K, et al. Pooled safety and adverse events in nine randomized, placebo-controlled, phase 2 and 3 clinical trials of alirocumab. Journal of the American College of Cardiology. 2015:A1363. 5479857
30. Kastelein J, Nissen S, Rader D, Krueger K, Wang MD. Safety and efficacy of LY 3015014, a new monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK 9) with an inherently longer duration of action, in patients with primary hypercholesterolemia: a randomized, placebo-controlled, dose-ranging, phase 2 study. Journal of the American College of Cardiology. 2015:A1591. 5479859
31. Kawashiri MA, Nohara A, Noguchi T, Tada H, Nakanishi C, Mori M, et al. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. American Journal of Cardiology 2012;109:364-9. 5479861
32. Mabuchi H, Nohara A. Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia. Nature Reviews Endocrinology 2015;11(1):8-9. 5479863
33. Maxwell KN, Breslow JL. Antibodies to PCSK9: a superior way to lower LDL cholesterol?. Circulation Research 2012;111:274-7. 5479865
34. Mearns BM. Dyslipidaemia: 1-year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab. Nature Reviews Cardiology 2014;11:63. 5479867
35. Pordy R, Lecorps G, Bessac L, Sasiela WJ, Ginsberg H. Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic dosing in phase 3 studies. Journal of Clinical Lipidology 2013;7(3):279. 5479869
36. Raal F, Nelson P, Langslet G, Basart DCG, Civeira F, Lopez-Miranda J, et al. Safety, tolerability, and efficacy of long-term administration of monthly AMG 145 in subjects with heterozygous familial hypercholesterolemia. Global Heart. 2014; Vol. 1:e139. 5479871
37. Raal F, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Honarpour N, et al. Long-term reduction in lipoprotein(A) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of 3278 patients in phase 2, 3, and open label extension studies. Circulation. 2014. 5479873
38. Shaywitz AJ, Dias C, Smith B, Gao B, Gibbs J, Emery M, et al. AMG 145, a fully human monoclonal antibody against PCSK9, reduces LDL-C in healthy volunteers and patients on stable doses of statins+. Journal of Clinical Lipidology. 2012; Vol. 6, issue 3:286-7. 5479875
39. Stawowy P, Just IA, Kaschina E. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia. Coronary Artery Disease 2014;25:353-9. 5479877
40. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. New England Journal of Medicine 2012;366:1108-18. 5479879
41. Stein EA, Somaratne R, Schou MB, Civeira F, Sullivan D, Watts GF, et al. Efficacy and tolerability of long-term treatment with AMG 145 in patients with statin intolerance. Circulation. 2013. 5479881
42. Swergold G, Biedermann S, Renard R, Nadler D, Wu R, Mellis S. Safety, lipid, and lipoprotein effects of REGN727/SAR236553, a fully-human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody administered intravenously to healthy volunteers. Circulation 2010;122:2. 5479883
43. Swergold G, Smith W, Mellis S, Logan D, Webb C, Wu R, et al. Inhibition of proprotein convertase subtilisin/kexin type 9 with a monoclonal antibody REGN727/SAR236553, effectively reduces low-density-lipoprotein cholesterol, as mono or add-on therapy in heterozygous familial and non familial hypercholesterolemia. Circulation. 2011; Vol. 124:2. 5479885
44. Wan H, Gumbiner B, Joh T, Udata C, Forgues P, Garzone PD. Effects of RN316 (pf-04950615), a humanized igg2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, on lipoprotein particles in hypercholesterolemic subjects. Journal of the American College of Cardiology. 2013:E1387. 5479887
45. Ridker PM, Tardif JC, Amarenco P, DUggan W, Glyn RJ, Jukema WJ, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine 2017;online first:1-10. 5479889
46. NCT02729025 . Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)). (ANITSCHKOW). https://clinicaltrials.gov/ct2/show/NCT02729025 (first received: March 8, 2016). 5479891
47. NCT02207634 . Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS). https://clinicaltrials.gov/ct2/show/NCT02207634 (first received July 31, 2014). 5479893
48. NCT02392559 . Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders (HAUSER-RCT). https://clinicaltrials.gov/ct2/show/NCT02392559 (first received February 25, 2015). 5479895
49. NCT02833844 . Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia. https://clinicaltrials.gov/ct2/show/NCT02833844 (first received June 13, 2016). 5479897
50. NCT02642159 . Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia). https://clinicaltrials.gov/ct2/show/NCT02642159 (first received December 24, 2015). 5479899
51. NCT01663402 . ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. https://clinicaltrials.gov/ct2/show/NCT01663402 (first received August 8, 2012). 5479901
52. NCT01624142 . Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG). https://clinicaltrials.gov/ct2/show/NCT01624142 (first received June 5, 2012). 5479903
53. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics 2013;34(2):154-6.
54. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
55. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. Journal of the American College of Cardiology 2010;55(22):2833-42.
56. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. Journal of Clinical Endocrinology and Metabolism 2012;97(11):3956-64.
57. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26(1):53-77.
58. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine 2015;372(25):2387-97.
59. Capewell S, Allender S, Critchley J, Lloyd-Williams F, O'Flaherty M, Rayner M, et al. Modelling the UK burden of cardiovascular disease to 2020: a research report for the Cardio & Vascular Coalition and the British Heart Foundation. British Heart Foundation, 2008. http://www.healthimpact.org.uk/Home/Links (accessed 01 February 2015).
60. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228(1):18-28.
61. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal 2016;Ahead of print:1-72.
62. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circulation. Cardiovascular Genetics. 2012;5(2):257-64.
63. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genetics 2005;37(2):161-5.
64. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine 2006;354(12):1264-72.
65. Collins R, Reith C, Emberson J, Armitage J, Baigent C, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;Ahead of print:1-30.
66. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78.
67. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2005;385(9976):1397-405.
68. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380(9841):581-90.
69. Farnier M. PCSK9: From discovery to therapeutic applications. Archives of Cardiovascular Disease 2014;107(1):58-66.
70. Food and Drug Administration Center for Drug Evaluation and Research. Briefing document Praluent (alirocumab) injection. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting 09-06-2015; Vol. BLA 125559.
71. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman J, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. New England Journal of Medicine 2016;22:2144-53.
72. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001;292(5520):1934-8.
73. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(1):1490-4.
74. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 2004;44(3):720-32.
75. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
76. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proceedings of the National Academy of Sciences 1987;84:6919-6923.
77. Knowles JW, O'Brein EC, Greendale K, Wilemon K, Genest J, Sperling LS, et al. Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. American Heart Journal 2014;168(6):807-11.
78. Kreatsoulas C, Anand SS. The impact of social determinants on cardiovascular disease. Canadian Journal of Cardiology 2010;26(Suppl C):8C-13C.
79. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Global Health 2013;1(5):e259-81.
80. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
81. Lipinsky MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. European Heart Journal 2016;37(6):536-45.
82. Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Willems SM, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes. JAMA 2016;13:1383-91.
83. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]
84. Lunven C, Paehler T, Poitiers F, Brunet A, Rey J, Hanotin C, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovascascular Therapy 2014;32(6):297-301.
85. Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology 2011;27(5):635-62.
86. Marks D, Thorogood M, Neil HAW, Humpries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168(1):1-14.
87. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014;129(14):1493-501.
88. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2197-223.
89. Navarese EP, Kołodziejczak M, Schulze V, Gurbel PA, Tantry U, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Annals of Internal Medicine 2015; Vol. 163, issue 1:40-51. [DOI: 10.7326/M14-2957]
90. Newcombe RG, Bender R. Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk. Evidence-Based Medicine 2014;19(1):6-8.
91. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 2016;315(15):1580-90.
92. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosedand undertreated in the general population:guidance for clinicians to prevent coronary heart disease. European Heart Journal 2013;34(45):3478-90.
93. Pfizer . Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor (accessed 24 April 2017).
94. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014.
95. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18-209.
96. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New England Journal of Medicine 2015;372(16):1500-9.
97. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716):735-42.
98. Schmidt AF, Hoes AW, Groenwold RH. Comments on 'the use of propensity scores and observational data to estimate randomized controlled trial generalizability bias' by Taylor R. Pressler and Eloise E. Kaizar, Statistics in Medicine 2013. Statistics in Medicine 2014;33(3):536-7.
99. Schmidt AF, Pearce LS, Wilkins JP, Overington JP, Hingorani A, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD011748]
100. Schmidt AF, Klungel OH, Nielen M, de Boer A, Groenwold RHH, Hoes AW. Tailoring treatments using treatment effect modification. Pharmacoepidemiology and Drug Safety 2016;25(4):355-62.
101. Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. The Lancet Diabetes & Endocrinology 2017;5:97-105.
102. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proceedings of the National Academy of Sciences of the United States of America 2003;100(3):928-33.
103. Sudhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science 1985;228(4701):815-22.
104. Sweeting MJ, Sutton AJ, Lambert, PC . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(1):1351-75.
105. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2014;385(9965):351-61.
106. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in Medicine 1999;18(20):2693-708.
107. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Statistics in Medicine 2002;21(11):1559-73.
108. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001;323(7321):1123-4.
109. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/ (accessed 01 February 2015).
110. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics 2013;45(11):1274-83.
111. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li QN, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Medicine 2015;13(123):1-19.